Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
van der Hoek S, Jongs N, Oshima M, Neuen BL, Stevens J, Perkovic V, Levin A, Mahaffey KW, Pollock C, Greene T, Wheeler DC, Jardine MJ, Heerspink HJL. van der Hoek S, et al. Among authors: neuen bl. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):748-758. doi: 10.2215/CJN.0000000000000161. Epub 2023 Mar 31. Clin J Am Soc Nephrol. 2023. PMID: 36999981 Free PMC article. Clinical Trial.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Koshino A, Neuen BL, Jongs N, Pollock C, Greasley PJ, Andersson EM, Hammarstedt A, Karlsson C, Langkilde AM, Wada T, Heerspink HJL. Koshino A, et al. Among authors: neuen bl. Cardiovasc Diabetol. 2023 Nov 28;22(1):330. doi: 10.1186/s12933-023-02027-8. Cardiovasc Diabetol. 2023. PMID: 38017482 Free PMC article. Clinical Trial.
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
Tsoukas MA, Woo V, Tobe SW, Slee A, Rapattoni W, Ang FG, Seufert J, Neuen BL, Arnott C, Mahaffey KW, Wheeler DC. Tsoukas MA, et al. Among authors: neuen bl. Diabetes Obes Metab. 2023 Jul;25(7):2038-2042. doi: 10.1111/dom.15057. Epub 2023 Apr 4. Diabetes Obes Metab. 2023. PMID: 36942888 No abstract available.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine MJ. Kang A, et al. Among authors: neuen bl. Diabetes Obes Metab. 2023 Aug;25(8):2151-2162. doi: 10.1111/dom.15091. Epub 2023 May 10. Diabetes Obes Metab. 2023. PMID: 37161691 Clinical Trial.
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.
Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)*. Collier W, et al. Among authors: neuen bl. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):183-192. doi: 10.2215/CJN.0000000000000050. Epub 2023 Jan 19. Clin J Am Soc Nephrol. 2023. PMID: 36754007 Free PMC article.
The authors reply.
Heerspink HJL, Jongs N, Neuen BL. Heerspink HJL, et al. Among authors: neuen bl. Kidney Int. 2023 Sep;104(3):617-618. doi: 10.1016/j.kint.2023.06.004. Kidney Int. 2023. PMID: 37599020 No abstract available.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
Fletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL. Fletcher RA, et al. Among authors: neuen bl. J Am Soc Nephrol. 2023 Dec 1;34(12):1965-1975. doi: 10.1681/ASN.0000000000000248. Epub 2023 Oct 25. J Am Soc Nephrol. 2023. PMID: 37876229 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
136 results